Eli Lilly and Company (NYSE:LLY) is Lilly Endowment Inc.’s Largest Position

Lilly Endowment Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 101,028,810 shares of the company’s stock after selling 1,515,000 shares during the quarter. Eli Lilly and Company makes up about 100.0% of Lilly Endowment Inc.’s investment portfolio, making the stock its largest holding. Lilly Endowment Inc. owned approximately 10.64% of Eli Lilly and Company worth $47,380,491,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its position in Eli Lilly and Company by 1.6% during the first quarter. Wellington Management Group LLP now owns 20,324,267 shares of the company’s stock valued at $6,979,760,000 after buying an additional 314,349 shares during the period. Geode Capital Management LLC boosted its position in shares of Eli Lilly and Company by 1.1% in the first quarter. Geode Capital Management LLC now owns 14,867,424 shares of the company’s stock worth $5,094,159,000 after purchasing an additional 159,964 shares during the period. Morgan Stanley boosted its position in shares of Eli Lilly and Company by 44.1% in the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after purchasing an additional 3,691,436 shares during the period. Norges Bank bought a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $3,416,206,000. Finally, Moneta Group Investment Advisors LLC boosted its position in shares of Eli Lilly and Company by 102,752.2% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock worth $1,992,374,000 after purchasing an additional 5,440,731 shares during the period. 81.38% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 2.7 %

Shares of LLY opened at $575.66 on Friday. Eli Lilly and Company has a twelve month low of $296.32 and a twelve month high of $601.84. The company has a market cap of $546.47 billion, a P/E ratio of 80.06, a P/E/G ratio of 2.47 and a beta of 0.32. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 1.63. The company’s fifty day simple moving average is $512.56 and its 200-day simple moving average is $438.41.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.13. The firm had revenue of $8.31 billion for the quarter, compared to analysts’ expectations of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period in the prior year, the business posted $1.25 earnings per share. As a group, analysts expect that Eli Lilly and Company will post 9.84 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend was Monday, August 14th. Eli Lilly and Company’s payout ratio is presently 62.87%.

Insider Transactions at Eli Lilly and Company

In other news, EVP Alonzo Weems sold 1,148 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total value of $678,445.04. Following the transaction, the executive vice president now directly owns 7,760 shares in the company, valued at $4,586,004.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Eli Lilly and Company news, EVP Alonzo Weems sold 1,148 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total transaction of $678,445.04. Following the transaction, the executive vice president now directly owns 7,760 shares in the company, valued at approximately $4,586,004.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $571.41, for a total transaction of $119,996,100.00. Following the transaction, the insider now owns 99,983,810 shares in the company, valued at $57,131,748,872.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,010,309 shares of company stock worth $21,095,701,670. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on LLY. Citigroup upped their price target on shares of Eli Lilly and Company from $360.00 to $525.00 and gave the stock a “buy” rating in a research report on Wednesday, July 26th. 22nd Century Group reiterated a “maintains” rating on shares of Eli Lilly and Company in a research report on Tuesday, June 27th. Cantor Fitzgerald restated an “overweight” rating and set a $630.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, September 5th. The Goldman Sachs Group upped their target price on shares of Eli Lilly and Company from $385.00 to $470.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 9th. Finally, Bank of America upped their target price on shares of Eli Lilly and Company from $500.00 to $600.00 in a research report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twenty have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $532.78.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.